BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysacc…
Biotechnology
US, San Rafael [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -35.49 | 153.75 | 238.34 | |
| Graham Fair Price | 50.32 | 16.85 | 11.21 | |
| PEG | -95.88 | 0.14 | -3.44 | |
| Price/Book | -4.67 | 3.24 | 3.40 | |
| Price/Cash Flow | 761.56 | 1278.48 | 148.39 | |
| Prices/Earnings | -55.01 | 46.38 | 103.11 | |
| Price/Sales | -11.50 | 25.35 | 28.65 | |
| Price/FCF | 761.56 | 1278.48 | 148.39 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.05 | 0.79 | 0.79 | |
| Operating Margin | 185.82 | 0.13 | 0.04 | |
| ROA | 115.92 | 0.01 | < 0.005 | |
| ROE | < 0.005 | 0.02 | 111.92 | |
| ROIC | < 0.005 | 0.01 | 168.94 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | < 0.005 | -0.18 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.56 | 4.76 | 743.32 | |
| EPS QOQ | -0.30 | 3.27 | 990.91 | |
| FCF QOQ | 1.37 | 2.40 | 74.80 | |
| Revenue QOQ | -0.02 | < 0.005 | -82.65 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 744.67 | 734.30 | -1.39 | |
| Days Sales Outstanding (DSO) | 88.63 | 88.38 | -0.28 | |
| Inventory Turnover | 0.12 | 0.12 | 1.41 | |
| Debt/Capitalization | 0.18 | 0.18 | -2.73 | |
| Quick Ratio | 1.46 | 1.55 | 6.00 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 26.02 | 26.86 | 3.26 | |
| Cash | 5.98 | 5.54 | -7.36 | |
| Capex | -0.12 | -0.18 | -45.13 | |
| Free Cash Flow | 0.60 | 0.07 | -88.57 | |
| Revenue | 3.09 | 3.44 | 11.23 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad